General Atlantic L.P. Has $153 Million Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

General Atlantic L.P. decreased its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 36.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 6,117,715 shares of the company’s stock after selling 3,564,103 shares during the quarter. Centessa Pharmaceuticals comprises approximately 5.3% of General Atlantic L.P.’s portfolio, making the stock its 8th largest holding. General Atlantic L.P.’s holdings in Centessa Pharmaceuticals were worth $153,004,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after acquiring an additional 979 shares in the last quarter. TD Waterhouse Canada Inc. bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter worth $25,000. Wells Fargo & Company MN grew its stake in shares of Centessa Pharmaceuticals by 42.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after acquiring an additional 1,008 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter worth $36,000. Finally, Legal & General Group Plc grew its stake in shares of Centessa Pharmaceuticals by 3.5% in the 3rd quarter. Legal & General Group Plc now owns 101,693 shares of the company’s stock worth $2,464,000 after acquiring an additional 3,437 shares in the last quarter. Institutional investors own 82.01% of the company’s stock.

Analyst Ratings Changes

CNTA has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Wells Fargo & Company lowered shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $35.00 to $42.00 in a research note on Monday, April 20th. Wolfe Research lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Truist Financial lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target for the company. in a research report on Monday, April 13th. Finally, Guggenheim lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Four equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $41.33.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the company’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the sale, the insider directly owned 62,085 shares of the company’s stock, valued at $1,870,000.20. This represents a 39.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.09% of the stock is currently owned by company insiders.

Centessa Pharmaceuticals Price Performance

CNTA opened at $39.75 on Wednesday. The firm has a market cap of $6.15 billion, a P/E ratio of -22.21 and a beta of 1.11. The firm has a 50-day moving average of $39.65 and a 200 day moving average of $31.04. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. Centessa Pharmaceuticals PLC Sponsored ADR has a fifty-two week low of $12.30 and a fifty-two week high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.14). On average, research analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.